← All trials
NCT01766323
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2012
- Primary completion
- Jun 1, 2013
- Completion date
- Aug 1, 2013
- First posted
- —
- Last posted
- —
- Enrollment
- 200
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Dr. Rajendra Prasad Government Medical CollegeLead sponsor
- Indira Gandhi Medical CollegeStudy director
- Indira Gandhi Medical CollegeStudy chair
- Bangalore Institute of OncologyStudy chair
- Ram Manohar Lohia Insitute of Medical SciencesStudy chair
- Dr. Rajendra Prasad Government Medical CollegeReponsible party - principal investigator
- Dr. Rajendra Prasad Government Medical CollegeOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.